AcouSort AB AI Stock Analysis
Want to see SE:ACOU full AI Analyst Report?
AcouSort AB (ACOU) AI Stock Analysis
AcouSort AB
(Nasdaq OMX AB:ACOU)
The score is held down primarily by weak financial performance—large operating losses, negative gross profit, and ongoing cash burn alongside shrinking equity—despite some revenue growth and a no-debt balance sheet. Technicals add further pressure, with price trading below all major moving averages and negative momentum signals. Valuation offers limited support because earnings are negative and no dividend yield is provided.
AcouSort AB (ACOU) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 57.14M
- Dividend Yield
- ―
- Average Volume (3M)
- 36.12K
- Price to Earnings (P/E)
- -5.2
- Beta (1Y)
- 0.05
- Revenue Growth
- 43.22%
- EPS Growth
- 36.11%
- Country
- Sweden
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
AcouSort AB Business Overview & Revenue Model
Company Description
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular v...
How the Company Makes Money
AcouSort AB makes money primarily by commercializing its acoustofluidic separation technology to customers who need to integrate cell/particle separation and washing into their instruments or manufacturing workflows. Key revenue streams include: (1)...
AcouSort AB Financial Statement Overview
Summary
Revenue is growing (TTM +7.6% to 7.97m) and losses have narrowed versus prior years, but overall financial quality remains weak due to deeply negative profitability (negative gross profit; EBIT -13.0m; net loss -11.2m) and persistent cash burn (TTM operating cash flow -6.6m; free cash flow -6.9m). Zero reported debt helps reduce solvency risk, yet equity has fallen sharply (to ~9.8m), increasing future funding/dilution risk.
Income Statement
18Very NegativeBalance Sheet
63PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.97M | 6.85M | 4.74M | 10.55M | 4.96M | 3.01M |
| Gross Profit | -7.90M | -14.50M | 4.77M | 8.39M | 2.91M | 548.00K |
| EBITDA | -12.17M | -14.33M | -15.89M | -16.70M | -12.86M | -11.46M |
| Net Income | -11.22M | -12.15M | -15.08M | -17.09M | -13.21M | -12.38M |
Balance Sheet | ||||||
| Total Assets | 21.47M | 17.89M | 12.32M | 34.51M | 42.66M | 36.56M |
| Cash, Cash Equivalents and Short-Term Investments | 9.48M | 6.29M | 3.57M | 23.99M | 33.97M | 31.52M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 11.67M | 1.59M | 3.86M | 10.38M | 22.54M | 3.54M |
| Stockholders Equity | 9.81M | 16.30M | 8.46M | 24.14M | 20.11M | 33.02M |
Cash Flow | ||||||
| Free Cash Flow | -6.91M | -17.27M | -19.84M | -31.77M | 2.95M | -12.23M |
| Operating Cash Flow | -6.58M | -16.78M | -18.81M | -31.56M | 3.96M | -10.92M |
| Investing Cash Flow | -1.39M | -488.00K | -1.02M | -1.16M | -1.01M | -1.31M |
| Financing Cash Flow | -118.00K | 18.98M | -157.00K | 22.08M | 0 | 35.63M |
AcouSort AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACOU, the sentiment is Negative. The current price of 2.61 is below the 20-day moving average (MA) of 3.16, below the 50-day MA of 3.02, and below the 200-day MA of 3.33, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 41.03 is Neutral, neither overbought nor oversold. The STOCH value of 19.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACOU.
AcouSort AB Peers Comparison
Overall Rating
SE:CEVI83Outperform
SE:FLUI65Neutral
SE:ACOU42Neutral
SE:BICO40Underperform
SE:IMMNOV39.1Underperform
SE:QLINEA38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | SEK 4.85B | 35.21 | 15.23% | 1.35% | 1.95% | -8.91% | |
| 65Neutral | SEK 35.99M | 7.25 | 34.47% | ― | 630.57% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | SEK 57.14M | -5.19 | -76.74% | ― | 43.22% | 36.11% | |
| 40Underperform | SEK 1.18B | -5.17 | -28.59% | ― | -5.27% | 34.38% | |
| 39Underperform | SEK 87.23M | -0.27 | -215.44% | ― | 148.66% | 66.30% | |
| 38Underperform | SEK 250.12M | -1.53 | -48.10% | ― | 33.26% | 90.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ACOU | AcouSort AB | 2.61 | -0.04 | -1.51% | |
| SE:BICO | BICO Group AB Class B | 15.58 | -3.15 | -16.82% | |
| SE:CEVI | CellaVision AB | 203.50 | 53.24 | 35.43% | |
| SE:IMMNOV | Immunovia AB | 0.03 | -0.15 | -82.97% | |
| SE:QLINEA | Q-linea AB | 12.60 | -13.46 | -51.65% | |
| SE:FLUI | Fluicell AB | 24.20 | 11.40 | 89.06% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
